Browse > Article

Treatment of Chronic Myofascial Pain with Botulinum Toxin : Case Report  

Hong, Seong-Ju (Department of Oral medicine, School of Dentistry, Chosun University)
Yoon, Chang-Lyuk (Department of Oral medicine, School of Dentistry, Chosun University)
Ahn, Jong-Mo (Department of Oral medicine, School of Dentistry, Chosun University)
Ryu, Ji-Won (Department of Oral medicine, School of Dentistry, Chosun University)
Publication Information
Journal of Oral Medicine and Pain / v.35, no.3, 2010 , pp. 221-227 More about this Journal
Abstract
MyoFascial Pain Syndrome(MFPS) is defined as a regional pain syndrome characterized by muscle pain caused by myofascial trigger points (MTrPs). Myofascial pain is a common cause of persistent regional pain such as neck pain, shoulder pain, headaches, and orofacial pain. Clinicians who deal with orofacial pain must also understand the role of myofascial pain. This case report presents the treatment of botulinum toxin A for chronic myofascial pain.
Keywords
Botulinum toxin A; Chronic pain; Myofascial pain; Orofacial pain;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sharav Y, Singer E, Schmidt E, et al.: The analgesic effect of amitriptyline on severe facial pain. Pain 1987;31:199-203.   DOI   ScienceOn
2 Qerama E, Fuglsang-Frederiksen A, Jensen TS. The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 2010; 23(5):602-610.   DOI   ScienceOn
3 Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanism of myofascial trigger points. Arch Phys Med Rehabil 1998;79:863-872.   DOI   ScienceOn
4 Svensson P, List T, Hector G. Analysis of stimulusevoked pain in patients with myofascial temporomandibular pain disorders. Pain 2001;92:399-409.   DOI   ScienceOn
5 Fricton JR, Kroening R, Haley D, Siegert R. Myofascial pain syndrome of the head and neck: a review of clinical characteristics of 164 patients. Oral Surg Oral Med Oral Pathol 1985;60:615-623.   DOI   ScienceOn
6 Aoki KR. Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. NeuroToxicology 2005;26:785 - 793.   DOI   ScienceOn
7 Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jawmuscle spindles. Acta Otolaryngol 1993;113:400 - 404.   DOI   ScienceOn
8 Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with Botulinum toxin A: A short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil 2005;84:649 - 654.   DOI   ScienceOn
9 Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;50:599 - 608.
10 Tarsy D, First ER. Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov Disord 1999;14:1043 - 1045.   DOI   ScienceOn
11 Kerr FW. A mechanism to account for frontal headache in cases of posterior fosse tumors. J Neurosurg 1961;18:605-609.   DOI
12 Al-Ani Z, Gray RJ, Davies SJ, Sloan P, Glenny AM. Stabilization splint therapy for the treatment of temporomandibular myofascial pain: a systematic review. J Dent Educ 2005;69(11):1242-1250.
13 Piovesan EJ, Werneck LC, Teive HA, et al. Neurophysiology of pain in tentorial irritation: description of a case secondary to medulloblastoma. Arq Neuropsiquiatr 1998;56:677-682.   DOI   ScienceOn
14 utchinson PJ, Pickard JD, Higgins JN: Vertebral artery dissection presenting as cerebellar infarction. J Neurol Neurosurg Psychiatry 2000;68:98-99.   DOI   ScienceOn
15 Tsuga K, Akagawa Y, Sakaguchi R, Tsuru H. A short-term evaluation of the effectiviness of stabilisation therapy for specific symptoms of temporomandibular joint dysfunction syndrome. J Prosthet Dent 1989;61:610-613.   DOI   ScienceOn
16 Gray RJM, Davies SJ, Quale AA. A comparison of two splints in the treatment of TMJ myofascial pain: can occlusal analysis be used to predict success of splint therapy? Br Dent J 1991;170:257-261.   DOI   ScienceOn
17 Davies SJ, Gray RJM. The pattern of splint usage in the management of two common temporomandibular disorders. Part III: Long-term follow-up in an assessment of splint therapy in the management of disc displacement with reduction and pain dysfunction syndrome. Br Dent J 1997;183:279-283.   DOI   ScienceOn
18 Fricton JR, Kroening R, Haley D, Siegert R. Myofascial pain syndrome of the head and neck: a review of clinical characteristics of 164 patients. Oral Surg Oral Med Oral Pathol 1985;60:615 - 623.   DOI   ScienceOn
19 Graff-Radford SB. Regional myofascial pain syndrome and headache: principles of diagnosis and management. Curr Pain Headache Rep 2001;5(4): 376-381.   DOI   ScienceOn
20 Majlesi J, Unalan H. Effect of treatment on trigger points. Curr Pain Headache Rep 2010;14(5):353-360.   DOI   ScienceOn
21 Hutchinson PJ, Pickard JD, Higgins JN. Vertebral artery dissection presenting as cerebellar infarction. J Neurol Neurosurg Psychiatry 2000;68:98–99.   DOI   ScienceOn
22 Travell JG, Simons DG. Myofascial Pain and Dysfunction: The Trigger Point Manual. Baltimore, 1983, Williams and Wilkins, pp 24-25.
23 Graff-Radford SB. Myofascial pain: diagnosis and management. Curr Pain Headache Rep 2004;8: 463-467.   DOI   ScienceOn
24 Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research group. Headache 2000;40:445 - 450.   DOI   ScienceOn
25 Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. Neurology 2001;56:1290 - 1293.   DOI   ScienceOn
26 Steinder A. The interpretation of the sciatic radiation and the syndrome of low back pain. J Bone Joint Surg 1940;22:28-34.
27 Jankovic J, Tintner R. Botulinum toxin for the treatment of cervical dystonia. Expert Opinion 2001;2:1985 - 1994.   DOI   ScienceOn
28 Abbott JA, Jarvis SK, Lyons SD, Thompson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: A randomized controlled trial. Obstet Gynecol 2006;108:915 - 923.   DOI   ScienceOn
29 Han SC, Harrison P. Myofascial pain syndrome and triggerpoint management. Reg Anesth 1997;22:89-101.   DOI   ScienceOn
30 Rand J, Whaler BC. Impairment of sympathetic transmission by Botulinum toxin. Nature 1965;206:588 - 591.   DOI   ScienceOn
31 Stohler CS. Masticatory myalgias. In Oral and Maxillofacial Surgery. Temporomandibular Disorders. Philadelphia, 2000, WB Saunders, pp.38 - 45.
32 Piovesan EJ, Werneck LC, Teive HA, et al. Neurophysiology of pain in tentorial irritation: description of a case secondary to medulloblastoma. Arq Neuropsiquiatr 1998;56:677-682.   DOI   ScienceOn
33 Piovesan EJ, Kowacs PA, Oshinsky ML. Convergence of cervical and trigeminal sensory afferents. Curr Pain Headache Rep 2003;7(5):377-83.   DOI   ScienceOn
34 Fricton JR. Myofascial pain: clinical characteristics and diagnostic criteria. J Musculoskel Pain 1993;1: 37-47.
35 Simons DG, Travell JG, Simons LS. Travell & Simons's Myofascial Pain and Dysfunction: The Trigger Point Manual. 2nd edi., Baltimore, 1999,Williams & Wilkins, pp. 11-86.
36 Fleckenstein J, Zaps D, Ruger LJ, et al. Discrepency between prevalence and perceived effectiveness of treatment methods in myofascial pain syndrome: Results of a cross-sectional, nationwide survey. BMC Musculoskelet Disord 2010;11:32-41.   DOI   ScienceOn